Waisman Biomanufacturing

Development and Analytical Services

Overview

With broad and comprehensive capabilities, Waisman Biomanufacturing is uniquely situated and highly qualified to lead clients through the complex process of bringing a novel vaccines and therapeutics into the clinic. Our Industry-Academia hybrid operational model starts with an industry-experienced leadership team that negotiates a flexible and time and cost-effective development plan that meets your needs. 

Subsequently, our highly collaborative Process Development, Manufacturing, and Quality Control scientific team works to translate your bench top process to a scalable biopharmaceutical manufacturing process. Using this strategy Waisman routinely produces CGMP grade material suitable for human clinical trials for a wide variety of applications. 

Cell Line Development

Microbial cell line development for plasmid DNA, recombinant proteins, and live biotherapeutic products.

Read more

Process Development

Full support for clinical process development including microbial fermentation, mammalian cell culture development, research cell banking, and downstream processing for recombinant proteins, plasmid DNA, and viral vectors/vaccines.

Read more

Analytical Services

Comprehensive product testing and analytical methods development/qualification/validation to support process development and CGMP release testing.

Read more

Stability and Comparability

Custom and phase-appropriate stability testing to support product use during toxicology and human clinical studies.

Read more